Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Real-world experience of oral cladribine use in the MSBase Registry
Multiple Sclerosis
P8 - Poster Session 8 (8:00 AM-9:00 AM)
9-003
In a real-world setting, we characterized demographics and early outcomes in MS patients treated with Cladribine
Cladribine is a recent addition to MS therapeutics and its real-world use has not been characterized
Secondary data analysis of MSBase Registry data including patients newly treated with cladribine after regulatory approval. Descriptive statistics to analyze baseline characteristics at time of cladribine initiation, including demographics, disease course and duration, prior disease modifying therapies (DMT), and EDSS. Occurrence of relapse was analyzed in patients with ≥6 months follow-up data. 
As of the 8th July 2019, MSBase included 317 patients newly treated with cladribine from 9 countries, mainly from Australia and Europe, including 260 RRMS patients and 44 with SPMS. Median age at cladribine initiation was 45 years in RRMS and 57.2 years in SPMS. Median time from diagnosis to cladribine initiation was longer in SPMS (20.3 years) than in RRMS (9.1 years). Median EDSS at cladribine start was 2.5 (IQR 1.5-4.0) and 6.5 (IQR 5.5-7.0) in RRMS and SPMS, respectively. 16.7% of patients initiated cladribine as first line therapy, and 36.7% had not been on another DMT in the prior 6 months. Patients switched primarily from fingolimod (18.3%) or natalizumab (12.1%). 207 patients with RRMS had ≥6 months follow-up, of whom 10 (4.8%) experienced ≥1 relapse. 32 patients who switched from Natalizumab had a median treatment gap of 1.2 months (IQR 1.0-2.05) and median follow-up was 5.2 months. Of these, 3 reported ≥1 relapse. Less than 10% of patients discontinued cladribine before 12 months.
MSBase patients newly treated with cladribine in a real- world clinical setting had a relatively high median EDSS and long disease duration in both RRMS and SPMS groups. Annualised relapse rate was <0.10 and treatment discontinuation in the first 12 months was rare. 
Authors/Disclosures
Helmut Butzkueven, MD, MBBS
PRESENTER 		Dr. Butzkueven has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Oxford Health Policy Forum. The institution of Dr. Butzkueven has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen. The institution of Dr. Butzkueven has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Merck. The institution of Dr. Butzkueven has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. The institution of Dr. Butzkueven has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche. Dr. Butzkueven has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for MSBase . The institution of Dr. Butzkueven has received research support from NHMRC. The institution of Dr. Butzkueven has received research support from Biogen. The institution of Dr. Butzkueven has received research support from Roche. The institution of Dr. Butzkueven has received research support from Novartis.
Timothy Spelman No disclosure on file
Sara Eichau Madueno Sara Eichau Madueno has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Sara Eichau Madueno has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Sara Eichau Madueno has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Sara Eichau Madueno has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Sara Eichau Madueno has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Sara Eichau Madueno has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Novartis. Sara Eichau Madueno has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. Sara Eichau Madueno has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Sanofi. Sara Eichau Madueno has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Merck.
Francois Grand-Maison, MD (Francois Grand'Maison MD INC) Dr. Grand-Maison has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Grand-Maison has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Dr. Grand-Maison has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Serono. Dr. Grand-Maison has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Grand-Maison has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis .
Tomas Kalincik Tomas Kalincik has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche. Tomas Kalincik has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi Genzyme. Tomas Kalincik has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Tomas Kalincik has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Merck. Tomas Kalincik has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Tomas Kalincik has received personal compensation in the range of $500-$4,999 for serving as a Consultant for National Health and Medical Research Council. Tomas Kalincik has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MS Research Australia. Tomas Kalincik has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Tomas Kalincik has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Tomas Kalincik has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi Genzyme. Tomas Kalincik has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Tomas Kalincik has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Tomas Kalincik has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Janssen. Tomas Kalincik has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol Myers Squibb. Tomas Kalincik has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for WebMD Global. Tomas Kalincik has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Novartis. Tomas Kalincik has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen. Tomas Kalincik has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Sanofi Genzyme. Tomas Kalincik has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Teva. Tomas Kalincik has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for BioCSL. Tomas Kalincik has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Merck. Tomas Kalincik has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Eisai. The institution of Tomas Kalincik has received research support from Biogen. The institution of Tomas Kalincik has received research support from Novartis. The institution of Tomas Kalincik has received research support from Genzyme. The institution of Tomas Kalincik has received research support from Roche. The institution of Tomas Kalincik has received research support from Celgene. The institution of Tomas Kalincik has received research support from Merck. The institution of Tomas Kalincik has received research support from MSBase Foundation. The institution of Tomas Kalincik has received research support from ARSEP and EDMUS Foundations. The institution of Tomas Kalincik has received research support from MS Research Australia. The institution of Tomas Kalincik has received research support from National Health and Medical Research Council. The institution of Tomas Kalincik has received research support from Australian Research Council. The institution of Tomas Kalincik has received research support from MS Society. The institution of Tomas Kalincik has received research support from Trish Foundation. Tomas Kalincik has a non-compensated relationship as a scientific leadership group chair with MSBase Foundation that is relevant to Â鶹´«Ã½Ó³»­ interests or activities.
Suzanne J. Hodgkinson, MD, MBBS, PhD, FRACP The institution of Dr. Hodgkinson has received research support from MERCK. The institution of Dr. Hodgkinson has received research support from Atara. The institution of Dr. Hodgkinson has received research support from Biogen . The institution of Dr. Hodgkinson has received research support from Genzyme. The institution of Dr. Hodgkinson has received research support from ROCHE. The institution of Dr. Hodgkinson has received research support from Novartis.
Olga Skibina (Neurosciences, Box Hill Hospital) Olga Skibina has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck.
Ernest G. Butler, MD, PhD, FRACP Dr. Butler has nothing to disclose.